Rexer Pharma Profile
Key Indicators
- Authorised Capital ₹ 4.00 M
as on 15-11-2024
- Paid Up Capital ₹ 4.00 M
as on 15-11-2024
- Company Age 28 Year, 27 Days
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 1.51 Cr
as on 15-11-2024
- Revenue 8.09%
(FY 2023)
- Profit 53.15%
(FY 2023)
- Ebitda 162.02%
(FY 2023)
- Net Worth 1.09%
(FY 2023)
- Total Assets 6.01%
(FY 2023)
About Rexer Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 4.00 M and a paid-up capital of Rs 4.00 M.
The company has closed loans amounting to ₹1.51 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Raghava Gureddygari, Sujana Seelam, and Madallapalli Mohan serve as directors at the Company.
- CIN/LLPIN
U24230TG1996PTC026005
- Company No.
026005
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Dec 1996
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Rexer Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Raghava Gureddygari  | Director | 20-Dec-1996 | Current |
| Sujana Seelam | Director | 23-Jan-2017 | Current |
| Madallapalli Mohan | Director | 20-Dec-1996 | Current |
Financial Performance of Rexer Pharma.
Rexer Pharma Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 8.09% increase. The company also saw a substantial improvement in profitability, with a 53.15% increase in profit. The company's net worth moved up by a moderate rise of 1.09%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rexer Pharma?
Unlock access to Rexer Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 09 Mar 2016 | ₹1.50 M | Satisfied |
Andhra Pradesh State Financial Corporation Creation Date: 30 Mar 2010 | ₹4.00 M | Satisfied |
Others Creation Date: 20 Jul 2007 | ₹2.00 M | Satisfied |
How Many Employees Work at Rexer Pharma?
Rexer Pharma has a workforce of 16 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rexer Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rexer Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
